コンテンツへスキップ
Merck
すべての画像(5)

主要文書

安全性情報

HPA009985

Sigma-Aldrich

抗PIK3CA ウサギ宿主抗体

Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution

別名:

抗PI3-キナーゼp110 サブユニットα抗体 ウサギ宿主抗体, 抗PI3K抗体 ウサギ宿主抗体, 抗PtdIns-3-キナーゼp110抗体 ウサギ宿主抗体, 抗ホスファチジルイノシトール-4,5-二リン酸 3-キナーゼ触媒サブユニットα-アイソフォーム抗体 ウサギ宿主抗体

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352203
Human Protein Atlas Number:

由来生物

rabbit

品質水準

結合体

unconjugated

抗体製品の状態

affinity isolated antibody

抗体製品タイプ

primary antibodies

クローン

polyclonal

製品種目

Prestige Antibodies® Powered by Atlas Antibodies

フォーム

buffered aqueous glycerol solution

交差性

human

テクニック

immunofluorescence: 1-4 μg/mL
immunohistochemistry: 1:50- 1:200

免疫原配列

EDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVK

UniProtアクセッション番号

アプリケーション

research pathology

輸送温度

wet ice

保管温度

−20°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

human ... PIK3CA(5290)

詳細

PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) is one of the four subunits of the 110kDa catalytic domain of PI3K protein, which contains a regulatory region of 85kDa. PI3K proteins form a family of lipid kinases. This gene is localized to human chromosome 3q.

免疫原

ホスファチジルイノシト-ル-4,5-二リン酸 3-キナ-ゼ触媒サブユニットα-アイソフォ-ムのPrEST(recombinant protein epitope signature tag)抗原リコンビナントタンパク質。

アプリケーション

Prestige抗体®は、Human Proteome Resource(HPR)プロジェクト(www.proteinatlas.org)によって開発・実証されたAtlas抗体です。抗体はすべて、数百の正常組織・疾病組織に対する免疫組織染色試験を行っています。これらの染色画像はHuman Protein Atlas(HPA)サイトで[Image Gallery]リンクをクリックするとご覧いただけます。さらに、ほとんどのPrestige抗体はプロテインアレイおよびウェスタンブロッティングの試験を行っています。試験のプロトコールおよびPrestige抗体、HPAに関する情報はsigma.com/prestigeをご覧ください。

生物化学的/生理学的作用

PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α) is one of the four catalytic subunits of PI3K protein, which plays an essential role in extracellular growth signaling. It phosphorylates and activates protein kinase B (PKB) protein. This protein has a wide range of physiological functions, and plays central role in multiple types of cancers. PIK3CA gene is either mutated or amplified in brain, breast, stomach, liver, ovary and colon cancers. Mutation in this gene leads to enhanced PI3K activity, and it is a candidate transforming oncogene. It is over-expressed in invasive breast cancer and is a marker for poor prognosis. This gene is amplified in high-grade dysplastic lesions from bronchial biopsy specimens obtained from preinvasive squamous lung cancer. Frequency of mutations in PIK3CA gene is higher in tumors without lymph node metastasis, than those within gastric cancer. Thus, it might be essential to evaluate the mutations in this gene to determine cetuximab treatment in gastric cancer patients.

特徴および利点

Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:
  • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
  • Protein array of 364 human recombinant protein fragments.

関連事項

Corresponding Antigen APREST86825.

物理的形状

PBS溶液 (pH 7.2, 40%グリセロ-ル, 0.02%アジ化ナトリウム含有)

法的情報

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください

保管分類コード

12 - Non Combustible Liquids

WGK

WGK 1

引火点(°F)

Not applicable

引火点(℃)

Not applicable

個人用保護具 (PPE)

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

HPA009985-100UL:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Si-Hyong Jang et al.
Journal of gastric cancer, 16(2), 85-92 (2016-07-20)
PIK3CA is often mutated in a variety of malignancies, including colon, gastric, ovary, breast, and brain tumors. We investigated PIK3CA expression in gastric cancer and explored the relationships between the PIK3CA expression level and clinicopathological features as well as survival
Frank McCaughan et al.
American journal of respiratory and critical care medicine, 182(1), 83-91 (2010-03-20)
Amplification of distal 3q is the most common genomic aberration in squamous lung cancer (SQC). SQC develops in a multistage progression from normal bronchial epithelium through dysplasia to invasive disease. Identifying the key driver events in the early pathogenesis of
Mohammed A Aleskandarany et al.
Breast cancer research and treatment, 122(1), 45-53 (2009-08-25)
The implications of Phosphatidylinositol 3-kinase (PIK3CA) mutations and its aberrant protein expression in breast cancer (BC) different molecular subtypes and patients' outcome remain controversial. The aims of this study were to assess the prevalence and clinical significance of PIK3CA protein
Piotr Laudański et al.
Folia histochemica et cytobiologica, 49(2), 317-324 (2011-07-12)
The aim of this study was to selectively profile the activation status of mammalian target of rapamycin (mTOR)-associated oncogenes and tumor suppressor genes (TSGs) in ovarian cancer specimens, healthy ovaries and benign ovarian tumors, including endometrial cysts. We used a
Maider Ibarrola-Villava et al.
Oncotarget, 6(29), 26935-26945 (2015-09-04)
Genetic and epigenetic alterations play an important role in gastric cancer (GC) pathogenesis. Aberrations of the phosphatidylinositol-3-kinase signaling pathway are well described. However, emerging genes have been described such as, the chromatin remodeling gene ARID1A. Our aim was to determine

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)